3/7/2006 1:29:55 PM
London-based cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) and EcoBiotics Ltd, a privately held drug discovery company based in Queensland, Australia, today announce the signature of an agreement under which Antisoma will evaluate and have an option to license early-stage anti-cancer compounds from EcoBiotics. Antisoma will choose up to three compounds from the EcoBiotics portfolio to evaluate during the next year. If these evaluations yield positive results, Antisoma will have rights to license up to two of the compounds for development as anti-cancer drugs on pre-agreed terms.
comments powered by